Hepatology · Article 185

Tenofovir or Entecavir: How Should First-Line Hepatitis B Therapy Be Chosen?

Hepatitis B first-line therapy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Hepatitis B first-line therapy clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Hepatitis B first-line therapy: practical clinical approach

This page focuses on Hepatitis B first-line therapy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Hepatitis B first-line therapy

Clinical takeaway: For Hepatitis B first-line therapy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Entecavir, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred high-barrier nucleos(t)ide analogues. Choice is individualized. TDF has extensive efficacy and pregnancy experience but can affect renal function and bone mineral density. TAF delivers lower systemic tenofovir exposure and is often favored when renal or bone risk is important. Entecavir is highly effective but should be used cautiously in patients with prior lamivudine resistance and must be dose-adjusted for renal impairment.

Virologic efficacy is excellent with all three

The practical differences are safety, resistance history, pregnancy data, cost and access.

Renal and bone health matter

TAF is often attractive in older patients or those with kidney/bone risk.

Resistance history matters

Prior lamivudine resistance can compromise entecavir’s resistance barrier.

Practical clinical algorithm

1. Review prior antiviral exposure and resistance.

2. Assess renal function and bone risk.

3. Consider pregnancy or pregnancy potential.

4. Choose TDF, TAF or entecavir according to comorbidity and access.

5. Monitor renal parameters for tenofovir-based therapy as appropriate.

6. Confirm sustained HBV DNA suppression.

Common mistakes to avoid

Choosing by viral load alone.
Using entecavir without asking about lamivudine resistance.
Ignoring renal function.
Assuming TAF and TDF have identical systemic exposure.
Switching stable therapy without a clinical reason.

Trainee takeaway

First-line HBV drugs are similarly potent; the best choice is usually determined by the patient’s kidney, bone, pregnancy and resistance profile.

Frequently asked questions

Which drug is best in pregnancy?

Tenofovir, particularly TDF, has the longest pregnancy safety experience; current guidance also addresses TAF in selected settings.

Which is best with osteoporosis?

TAF or entecavir may be preferred over TDF.

Is entecavir safe with prior lamivudine resistance?

It is less attractive because resistance risk is higher.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

3. Ghany MG, Pan CQ, Lok AS, et al. AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B. Hepatology. 2026;83:974-997. doi:10.1097/HEP.0000000000001549.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions